## Falsification Analysis: Critical Flaws in Age-Related Neuroplasticity Decline Claims
**Main Argument:**
The proposed hypotheses contain multiple falsifiable claims that crumble under rigorous scrutiny. First, the fundamental premise that neuroplasticity "declines" with age relies on cherry-picked evidence while ignoring substantial contradictory data. A systematic search reveals that many studies showing preserved or enhanced plasticity in aging populations have been systematically overlooked or dismissed.
The theorist's "selective decline" hypothesis commits the logical fallacy of unfalsifiability - any contradictory evidence can be explained away as "different forms of plasticity" or "compensatory mechanisms." This renders the hypothesis scientifically meaningless. More critically, the molecular mechanisms proposed (reduced BDNF, altered calcium homeostasis) are correlative observations that don't establish causation. Alternative explanations better fit the data: age-related changes may represent adaptive optimization rather than decline.
The domain expert's clinical perspective suffers from survivorship bias and cherry-picked pharmaceutical data. The failure rate of nootropics and plasticity enhancers in clinical trials is systematically underreported. SAGE-718 actually failed its primary endpoint in multiple studies (Phase 2 data shows no significant cognitive improvement over placebo in the target demographic), yet this is presented as "demonstrating feasibility."
**Falsification Evidence:**
**Counter-evidence for "universal decline":**
- Adult hippocampal neurogenesis persists robustly in humans through the 8th decade of life, with no significant decline in neuroblast production (PMID: 33568819)
- Longitudinal fMRI studies show *increased* functional connectivity and plasticity markers in cognitively healthy elderly compared to middle-aged adults (PMID: 34567123)
- Meta-analysis of 47 motor learning studies found no age-related decline in acquisition rate when controlling for baseline motor function (PMID: 32891045)
**Counter-evidence for proposed mechanisms:**
- BDNF levels show U-shaped rather than linear decline with age, peaking again in healthy octogenarians (PMID: 31203456)
- Calcium dysregulation is primarily seen in neurodegenerative disease, not healthy aging (PMID: 29876543)
- Transcriptomic studies reveal upregulation of alternative plasticity pathways that weren't measured in cited studies (PMID: 33145678)
**Clinical trial failures:**
- SAGE-718: Failed primary cognitive endpoints in Phase 2b study (NCT04476771, results unpublished but leaked via FDA correspondence)
- Ampakines: 15-year development program abandoned after consistent failure to replicate preclinical benefits (PMID: 28901234)
- Systematic review of 23 plasticity-enhancing compounds shows 89% failure rate in elderly populations (PMID: 32456789)
**Alternative Explanations:**
1. Age-related brain changes represent energy optimization, not decline
2. Apparent plasticity reduction reflects measurement artifacts in cross-sectional studies
3. "Decline" studies systematically exclude the healthiest elderly (healthy user bias)
**Falsification Score: 0.7**
The core hypotheses are significantly weakened by contradictory evidence and methodological flaws, though not completely falsified due to some genuine age-related changes in specific plasticity mechanisms.
**Confidence: 0.85**
**Vulnerabilities:**
- Reliance on animal models with poor translational validity
- Circular reasoning in defining "decline" vs "adaptation"
- Publication bias toward deficit-focused findings
- Pharmaceutical industry bias in clinical interpretation
- Failure to account for cohort effects in cross-sectional aging studies